BUSULFAN injection

Country: United States

Language: English

Source: NLM (National Library of Medicine)

Active ingredient:

BUSULFAN (UNII: G1LN9045DK) (BUSULFAN - UNII:G1LN9045DK)

Available from:

Mylan Institutional LLC

INN (International Name):

BUSULFAN

Composition:

BUSULFAN 6 mg in 1 mL

Administration route:

INTRAVENOUS

Prescription type:

PRESCRIPTION DRUG

Therapeutic indications:

Busulfan injection is indicated for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia. Busulfan injection is contraindicated in patients with a history of hypersensitivity to any of its components. Busulfan can cause fetal harm when administered to a pregnant woman based on animal data. Busulfan was teratogenic in mice, rats, and rabbits following administration during organogenesis. The solvent, DMA, may also cause fetal harm when administered to a pregnant woman. In rats, DMA doses of approximately 40% of the daily dose of DMA in the busulfan dose on a mg/m2 basis given during organogenesis caused significant developmental anomalies (see Data) . There are no available human data informing the drug-associated risk. Advise pregnant women of the potential risk to a fetus. The background risk of major birth defects and miscarriage for the indicated populations are unknown. However, the background

Product summary:

Busulfan Injection is packaged as a sterile solution in 10 mL single-dose clear glass vials, NDC 67457-893-00. Busulfan Injection is distributed as a unit carton of eight vials, NDC 67457-893-08. Unopened vials of busulfan injection must be stored under refrigerated conditions between 2°C to 8°C (36°F to 46°F). Discard unused portion. Busulfan injection diluted in 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP is stable at room temperature (25°C) for up to 8 hours but the infusion must be completed within that time. Busulfan injection diluted in 0.9% Sodium Chloride Injection, USP is stable at refrigerated conditions (2°C to 8°C) for up to 12 hours but the infusion must be completed within that time. Busulfan injection is a cytotoxic drug. Follow applicable special handling and disposal procedures.1

Authorization status:

Abbreviated New Drug Application

Summary of Product characteristics

BUSULFAN- BUSULFAN INJECTION
MYLAN INSTITUTIONAL LLC
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
BUSULFAN INJECTION SAFELY AND
EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR BUSULFAN INJECTION.
BUSULFAN INJECTION, FOR INTRAVENOUS USE
INITIAL U.S. APPROVAL: 1999
WARNING: MYELOSUPPRESSION
_SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._
•
•
INDICATIONS AND USAGE
Busulfan injection is an alkylating drug indicated for:
•
DOSAGE AND ADMINISTRATION
•
•
•
DOSAGE FORMS AND STRENGTHS
Injection: 60 mg/10 mL (6 mg/mL) single-dose vial (3)
CONTRAINDICATIONS
Busulfan injection is contraindicated in patients with a history of
hypersensitivity to any of its components (4)
WARNINGS AND PRECAUTIONS
•
•
•
•
ADVERSE REACTIONS
Most common adverse reactions (incidence > 60%) were:
myelosuppression, nausea, stomatitis, vomiting, anorexia,
diarrhea, insomnia, fever, hypomagnesemia, abdominal pain, anxiety,
headache, hyperglycemia and hypokalemia (6.1)
TO REPORT SUSPECTED ADVERSE REACTIONS, CONTACT MYLAN AT 1-877-446-3679
(1-877-4-INFO-RX) OR FDA AT
1-800-FDA-1088 OR WWW.FDA.GOV/MEDWATCH.
DRUG INTERACTIONS
•
•
CAUSES SEVERE AND PROLONGED MYELOSUPPRESSION. (5.1)
HEMATOPOIETIC PROGENITOR CELL TRANSPLANTATION IS REQUIRED TO PREVENT
POTENTIALLY FATAL COMPLICATIONS
OF THE PROLONGED MYELOSUPPRESSION. (5.1)
Use in combination with cyclophosphamide as a conditioning regimen
prior to allogeneic hematopoietic progenitor
cell transplantation for chronic myelogenous leukemia (CML) (1)
Pre-medicate with anticonvulsants (e.g., benzodiazepines, phenytoin,
valproic acid or levetiracetam) and antiemetic
(2.1, 5.2)
Dilute and administer as intravenous infusion. Do not administer as
intravenous push or bolus (2.1, 2.3)
Recommended adult dose: 0.8 mg per kg of ideal body weight or actual
body weight, whichever is lower,
administered intravenously via a central venous catheter as a two-hour
infusion every six hours for four consecutive
days for a